Study of WJ22096 tablets for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new oral drug (WJ22096) for people with advanced solid tumors that have stopped responding to or cannot tolerate standard treatments. It may be an option if you are generally healthy enough to take part.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with an advanced solid tumor that standard therapy can no longer help.
- You need to be well enough to be up and about (ECOG 0 or 1) and have a life expectancy over 12 weeks.
- Your blood counts and organ function must meet certain levels (e.g., adequate white blood cells, platelets, and liver/kidney function) without recent transfusions or growth factors.
- You cannot have had certain previous treatments (like a FAK inhibitor) and must have a washout period from other cancer therapies.
- You must be able to take oral medication and not have active brain metastases, uncontrolled infections, or serious health conditions like heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether WJB001 capsules can treat advanced solid tumors in adults whose cancer has progressed after standard treatment (or who cannot take standard treatment). It also studies side effects and whether the drug can work for certain tumor types and genetic markers.
This trial is testing a new oral drug called HW221043 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and how well it works.
This trial studies a new drug called HW071021 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can help shrink or control the cancer.
This trial tests a new oral tablet, YY2201, for people with advanced cancer that has stopped responding to other treatments. The goal is to find a safe dose and see if it helps shrink or slow the cancer.
This trial tests a new investigational drug (JNJ-87890387) for people with certain advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
This trial tests a new combination drug for people with advanced solid tumors, especially certain gynecologic cancers, that have not responded to standard treatments. The treatment aims to target a specific genetic marker (CCNE1) found in the tumor.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.